Kumar Sambamurti to Cholinesterase Inhibitors
This is a "connection" page, showing publications Kumar Sambamurti has written about Cholinesterase Inhibitors.
Connection Strength
0.692
-
Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. Curr Pharm Des. 2004; 10(25):3111-9.
Score: 0.234
-
Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002; 14 Suppl 1:77-91.
Score: 0.203
-
The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J Pharmacol Exp Ther. 2007 Jan; 320(1):386-96.
Score: 0.071
-
Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer beta-amyloid peptide in rodent. Proc Natl Acad Sci U S A. 2005 Nov 22; 102(47):17213-8.
Score: 0.066
-
An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res. 2005 Jul; 2(3):281-90.
Score: 0.065
-
The effect of tacrine and leupeptin on the secretion of the beta-amyloid precursor protein in HeLa cells. Life Sci. 1997; 61(20):1985-92.
Score: 0.036
-
Identification of novel small molecule inhibitors of amyloid precursor protein synthesis as a route to lower Alzheimer's disease amyloid-beta peptide. J Pharmacol Exp Ther. 2006 Aug; 318(2):855-62.
Score: 0.017